Fig. 7.

CB₁ receptor inhibition attenuates diabetes-induced proapoptotic MAPK activation in vivo and in HREC. a Western blot of mice retinal lysate showing an increase in the activation of p38MAPK in diabetic (Diab) as compared with the vehicle (Veh)-treated controls; the increase was mitigated by SR 141716A (SR1) treatment (n=4–6). b Statistical analysis of above results (a), indicating a 2.4-fold increase. c Western blot of HREC cell lysate showing significant increases in activation of p38MAPK and JNK in cells maintained in high glucose (HG; 30 mmol/l D-glucose) as compared with cells maintained in normal glucose. These increases were mitigated upon treatment with SR 141716A (2 μmol/l). d, e Statistical analysis of above (c) findings for MAPK and JNK respectively. *p<0.05 vs vehicle group; ^†p<0.05 vs diabetes